The purchasing managers' index (PMI) for China's non-manufacturing sector dropped from the 56.4 it posted in November to 55.7 in December according to the National Bureau of Statistics (NBS). It has remained above 50 for 10 consecutive months.
A reading below 50 reflects contraction.
The service sector experienced a slower recovery, with the sub-index for business activities standing down to 54.8 in December from 55.7 in November.
The construction industry experienced robust growth with its sub-index for business activities increasing from 60.5 in November to 60.7 in December.
Meanwhile, the sub-indexes for business activities of telecommunications and satellite transmission, civil aviation, and financial services, remained above 60.
China has reduced taxes and fees and provided firms with low-cost loans to help them tide over difficulties brought by the pandemic.


Sika Raises 2026 Sales Outlook After Strong First-Half Results Beat Expectations
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth
Nvidia Eyes $250B Guarantee for OpenAI’s Massive Ohio AI Data Center Project
CATL Shares Jump as $5.6 Billion Buyback Signals Confidence in Long-Term Growth
Brown-Forman Rejects Sazerac’s $15 Billion Takeover Bid as Family Backs Independence
BHP, Port Hedland Unions Fail to Reach Wage Deal as Negotiations Continue
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9%
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation
Seagate Stock Jumps as AI-Fueled Earnings Beat and Strong FY2027 Outlook Impress Investors
Nvidia Invests $1 Billion in Naver as South Korea AI Data Center Expansion Gains Momentum
Zabka Shares Drop 10% as Seven & i Abandons Investment Plans
Air Liquide Q2 Sales Growth Tops Forecast as Electronics Business Drives Strong Performance
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns
Unilever Raises 2026 Sales Outlook After Strong Q2 Volume Growth
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth 



